2020 Year in Review - Neuroendocrine Tumors
2020 Year in Review - Neuroendocrine Tumors | January 9, 2021
Combined data from two phase 2 trials indicate that avelumab monotherapy had limited antitumor activity in patients with grade 2/3 neuroendocrine neoplasms (NENs).